PGP and plasma cell myeloma: In multiple myeloma, the presence of P-gp on circulating monoclonal B cells may not only confer resistance to conventional chemotherapy, but could also affect their interaction with and susceptibility to antibody–drug conjugates or CAR-T cell therapies targeting these malignant B cells [6].